Tamoxifen and testolactone in therapy of oligozoospermia: results of a randomized study.

Abstract

40 patients with oligoasthenozoospermia in infertile marriages were subjected to randomized treatment with 30 mg tamoxifen/day (n = 20), or with 30 mg tamoxifen/day and 150 mg testolactone/day (n = 20), to prevent elevation of estradiol levels during monotherapy with tamoxifen. In both groups there was a significant increase in FSH, LH and testosterone. The elevation of estradiol serum levels was significant (p less than 0.0001) in the tamoxifen group, and not significant in the group with combination therapy. The increase in sperm density was significant in both groups (p less than 0.001; p less than 0.002, respectively), but no differences were seen between both groups. No improvement of the other ejaculate parameters was seen in either groups. The incidence of gravidity was the same under additional testolactone therapy (n = 3).

• Authors: U Maier, G Hienert
• Journal: European urology (Eur Urol) Vol. 14 Issue 6 Pg. 447-9 ( 1988) ISSN: 0302-2838 [Print] Switzerland
• PMID: 3141194 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Tamoxifen
• Testosterone
• Testolactone
• Luteinizing Hormone
• Follicle Stimulating Hormone

Topics

• Drug Therapy, Combination
• Follicle Stimulating Hormone (blood)
• Humans
• Luteinizing Hormone (blood)
• Male
• Oligospermia (drug therapy)
• Random Allocation
• Sperm Count (drug effects)
• Tamoxifen (therapeutic use)
• Testolactone (therapeutic use)
• Testosterone (blood)